talquetamab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
rat origin	5742	2226212-40-2

Description:

Molecule	Description
Molfile Synonyms: talquetamab talquetamab-tgvs JNJ-64407564 talvey	Talquetamab-tgvs is a bispecific T-cell engaging antibody that binds to the CD3 receptor expressed on the surface of T-cells and G protein-coupled receptor class C group 5 member D (GPRC5D) expressed on the surface of multiple myeloma cells and non-malignant plasma cells, as well as healthy tissues such as epithelial cells in keratinized tissues of the skin and tongue. In vitro, talquetamab-tgvs activated T-cells caused the release of proinflammatory cytokines and resulted in the lysis of multiple myeloma cells. Talquetamab-tgvs had anti-tumor activity in mouse models of multiple myeloma. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Molfile

Synonyms:

talquetamab
talquetamab-tgvs
JNJ-64407564
talvey

Talquetamab-tgvs is a bispecific T-cell engaging antibody that binds to the CD3 receptor expressed on the surface of T-cells and G protein-coupled receptor class C group 5 member D (GPRC5D) expressed on the surface of multiple myeloma cells and non-malignant plasma cells, as well as healthy tissues such as epithelial cells in keratinized tissues of the skin and tongue. In vitro, talquetamab-tgvs activated T-cells caused the release of proinflammatory cytokines and resulted in the lysis of multiple myeloma cells. Talquetamab-tgvs had anti-tumor activity in mouse models of multiple myeloma.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Aug. 9, 2023	FDA	JANSSEN BIOTECH

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Relapsed or refractory multiple myeloma	indication	109989006	DOID:9538

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
T-cell surface glycoprotein CD3	Surface antigen	P07766 P09693 P04234	CD3E_HUMAN CD3G_HUMAN CD3D_HUMAN	ANTIBODY BINDING	EC50	7.82		DRUG LABEL	DRUG LABEL
G-protein coupled receptor family C group 5 member D	GPCR	Q9NZD1	GPC5D_HUMAN	ANTIBODY BINDING	EC50	6.72		DRUG LABEL	DRUG LABEL

External reference:

ID	Source
CHEMBL4594503	ChEMBL_ID
12240	IUPHAR_LIGAND_ID
DB16678	DRUGBANK_ID
C5419330	UMLSCUI
11173	INN_ID
2644447	RXNORM
D12180	KEGG_DRUG
4W3KFI3TN3	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
TALVEY	HUMAN PRESCRIPTION DRUG LABEL	1	57894-469	INJECTION	3 mg	SUBCUTANEOUS	BLA	30 sections
TALVEY	HUMAN PRESCRIPTION DRUG LABEL	1	57894-470	INJECTION	40 mg	SUBCUTANEOUS	BLA	30 sections